Stock market analyst Anil Singhvi has maintained 'buy' rating on Sun Pharmaceutical Industries Limited stock with an intra-day target of Rs 2450.

According to analyst, the stock can be purchased with a stop loss of Rs 2300.

The stock of the company, on Nov 11, closed at Rs 2331.90 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 2349 and a low of Rs 1407 on BSE.

Current EPS & P/E ratio stood at 86.97 and 27.16 respectively.

Taro Pharmaceutical Industries Ltd. stockholder Templeton Asset Management Ltd. has sold its equity stake in the company in order to make a handsome profit, after combating on both sides in the years-long legal clash for control of Taro.

Sun Pharmaceuticals Ltd has purchased Templeton's Taro stake for around $82 million.

Sun increase its holding stake in Taro to 65.2% as against 53.2%.

Sun Pharmaceutical Industries announced that its consolidated net profit for July-September period grew by 11% to Rs 5.04 billion as against Rs 4.53 billion during the corresponding period of 2009.

The company bagged USFDA's nod for an Abbreviated New Drug Application (ANDA) to sell a generic edition of Venlafaxine Hydrochloride Extended Release tabs.

Company's net sales/income surged 16% to Rs 13.70 billion in the three month period ended September 2010.

Operating profit climbed 36% to Rs 10.08 billion.